OBJECTIVES: Inversion of the CD4:CD8 ratio (< 1) has been identified as a hallmark of inmmunosenescence and an independent predictor of mortality in the general population. We aimed to assess the association between the CD4:CD8 ratio and markers of age-associated disease in treated HIV-infected patients with good immunovirological response. METHODS: A cross-sectional analysis was conducted in 132 HIV-infected adults on antiretroviral therapy (ART), with plasma HIV RNA < 50 HIV-1 RNA copies/mL for at least 1 year, CD4 count > 350 cells/μL and age < 65 years. We analysed the associations between the CD4:CD8 ratio and subclinical atherosclerosis [assessed using carotid intima-media thickness (IMT)], arterial stiffness [assessed using the augmentation index (AIx)], the estimated glomerular filtration rate (eGFR), muscle wasting and sarcopenia [assessed using appendicular lean mass/height(2) (ALM) measured by dual-energy X-ray absorptiometry (DEXA)]. RESULTS: CD4:CD8 ratio inversion was associated with higher IMT, lower eGFR and lower ALM (all values P < 0.05), but not with AIx. In multivariate analyses adjusted for age, sex, hypertriglyceridaemia, tobacco use and cumulative ART exposure, inversion of the CD4:CD8 ratio was independently associated with higher IMT [odds ratio (OR) 2.9; 95% confidence interval (CI) 1.2-7.1], arterial stiffness (OR 4.8; 95% CI 1.0-23.5) and lower eGFR (OR 5.2; 95% CI 1.0-64.4), but not sarcopenia (OR 0.7; 95% CI 0.2-2.7). These associations persisted when models were applied to subjects with nadir CD4 counts > 200 cells/μL and those with CD4 counts > 500 cells/μL. CONCLUSIONS: The CD4:CD8 ratio in treated HIV-infected subjects with good immunovirological response is independently associated with markers of age-associated disease. Hence, it might be a clinically useful predictor of non-AIDS-defining conditions.
OBJECTIVES: Inversion of the CD4:CD8 ratio (< 1) has been identified as a hallmark of inmmunosenescence and an independent predictor of mortality in the general population. We aimed to assess the association between the CD4:CD8 ratio and markers of age-associated disease in treated HIV-infectedpatients with good immunovirological response. METHODS: A cross-sectional analysis was conducted in 132 HIV-infected adults on antiretroviral therapy (ART), with plasma HIV RNA < 50 HIV-1 RNA copies/mL for at least 1 year, CD4 count > 350 cells/μL and age < 65 years. We analysed the associations between the CD4:CD8 ratio and subclinical atherosclerosis [assessed using carotid intima-media thickness (IMT)], arterial stiffness [assessed using the augmentation index (AIx)], the estimated glomerular filtration rate (eGFR), muscle wasting and sarcopenia [assessed using appendicular lean mass/height(2) (ALM) measured by dual-energy X-ray absorptiometry (DEXA)]. RESULTS:CD4:CD8 ratio inversion was associated with higher IMT, lower eGFR and lower ALM (all values P < 0.05), but not with AIx. In multivariate analyses adjusted for age, sex, hypertriglyceridaemia, tobacco use and cumulative ART exposure, inversion of the CD4:CD8 ratio was independently associated with higher IMT [odds ratio (OR) 2.9; 95% confidence interval (CI) 1.2-7.1], arterial stiffness (OR 4.8; 95% CI 1.0-23.5) and lower eGFR (OR 5.2; 95% CI 1.0-64.4), but not sarcopenia (OR 0.7; 95% CI 0.2-2.7). These associations persisted when models were applied to subjects with nadir CD4 counts > 200 cells/μL and those with CD4 counts > 500 cells/μL. CONCLUSIONS: The CD4:CD8 ratio in treated HIV-infected subjects with good immunovirological response is independently associated with markers of age-associated disease. Hence, it might be a clinically useful predictor of non-AIDS-defining conditions.
Authors: C Wyatt Shields; Carissa E Livingston; Benjamin B Yellen; Gabriel P López; David M Murdoch Journal: Biomicrofluidics Date: 2014-07-01 Impact factor: 2.800
Authors: Vitor H F Oliveira; Ana L Borsari; Allison R Webel; Kristine M Erlandson; Rafael Deminice Journal: Eur J Clin Nutr Date: 2020-04-27 Impact factor: 4.016
Authors: Jessica L Castilho; Megan Turner; Bryan E Shepherd; John R Koethe; Sally S Furukawa; Carmen E Bofill; Stephen Raffanti; Timothy R Sterling Journal: AIDS Res Hum Retroviruses Date: 2019-09-17 Impact factor: 2.205
Authors: Matteo Vassallo; R Fabre; J Durant; C Lebrun-Frenay; H Joly; M Ticchioni; F DeSalvador; A Harvey-Langton; B Dunais; M Laffon; J Cottalorda; P Dellamonica; C Pradier Journal: J Neurovirol Date: 2016-11-04 Impact factor: 2.643
Authors: Kathy Petoumenos; Jun Yong Choi; Jennifer Hoy; Sasisopin Kiertiburanakul; Oon Tek Ng; Mark Boyd; Reena Rajasuriar; Matthew Law Journal: Antivir Ther Date: 2017
Authors: Jessica L Castilho; Bryan E Shepherd; John Koethe; Megan Turner; Sally Bebawy; James Logan; William B Rogers; Stephen Raffanti; Timothy R Sterling Journal: AIDS Date: 2016-03-27 Impact factor: 4.177
Authors: Yean K Yong; Esaki M Shankar; Ajantha Solomon; Tim Spelman; Christopher K Fairley; Julian H Elliott; Jennifer Hoy; Paul U Cameron; Adeeba Kamarulzaman; Sharon R Lewin Journal: AIDS Date: 2016-09-10 Impact factor: 4.177